文献速递慢性肾脏病遗传性与小管间质肾病

博舒替尼对比安慰剂治疗常染色体显性多囊肾病

Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease.
PubMed 文献 · J Am Soc Nephrol · 2017-08-24

这项2期多中心研究评估博舒替尼(口服双Src/Bcr-Abl酪氨酸激酶抑制剂)对常染色体显性多囊肾病(ADPKD)的疗效与安全性。患者随机接受博舒替尼200mg/d、400mg/d或安慰剂治疗≤24个月。结果显示博舒替尼200mg/d使肾脏年增大率降低66%(1.63% vs 4.74%,P=0.01),合并博舒替尼组降低82%(0.84% vs 4.74%,P<0.001),但eGFR年下降率相似。胃肠道和肝脏不良事件最常见。

要点

  • 博舒替尼200mg/d可使ADPKD患者肾脏年增大率降低66%。
  • 博舒替尼未改变eGFR年下降率。
  • 胃肠道和肝脏相关不良事件是最常见毒性。

核心结论

  • 与安慰剂相比,博舒替尼200mg/d可减少ADPKD患者的肾脏增长。
  • 博舒替尼的总体胃肠道和肝脏毒性特征与既往研究一致,未发现新毒性。

研究设计与样本

  • 2期多中心研究,纳入eGFR≥60 ml/min per 1.73 m2且总肾脏体积≥750 ml的ADPKD患者。
  • 患者按1:1:1随机接受博舒替尼200 mg/d、400 mg/d或安慰剂治疗≤24个月。
  • 主要终点为治疗≥2周且至少有一次基线后磁共振成像(之前有30天洗脱期)患者的肾脏年增大率(改良意向治疗人群)。
  • 共入组172例患者,169例至少接受一次研究药物;根据方案修订,24例初始接受400 mg/d的患者后来减至200 mg/d。

主要发现

  • 博舒替尼200 mg/d组肾脏年增大率为1.63%,安慰剂组为4.74%,降低66%(P=0.01)。
  • 合并博舒替尼组肾脏年增大率为0.84%,安慰剂组为4.74%,降低82%(P<0.001)。
  • 治疗期间,安慰剂组与博舒替尼组的eGFR年下降率相似。
  • 胃肠道和肝脏相关不良事件是最常见的毒性。

临床怎么用

  • 博舒替尼200 mg/d可能用于减缓ADPKD患者的肾脏增大,但需关注胃肠道和肝脏毒性。
  • 该研究未显示博舒替尼对eGFR下降有明显影响,临床决策需综合评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Overactivation of Src has been linked to the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). This phase 2, multisite study assessed the efficacy and safety of bosutinib, an oral dual Src/Bcr-Abl tyrosine kinase inhibitor, in patients with ADPKD. Patients with ADPKD, eGFR≥60 ml/min per 1.73 m2, and total kidney volume ≥750 ml were randomized 1:1:1 to bosutinib 200 mg/d, bosutinib 400 mg/d, or placebo for ≤24 months. The primary endpoint was annualized rate of kidney enlargement in patients treated for ≥2 weeks who had at least one postbaseline magnetic resonance imaging scan that was preceded by a 30-day washout (modified intent-to-treat population). Of 172 enrolled patients, 169 received at least one study dose. Per protocol amendment, doses for 24 patients who initially received bosutinib at 400 mg/d were later reduced to 200 mg/d. The annual rate of kidney enlargement was reduced by 66% for bosutinib 200 mg/d versus placebo (1.63% versus 4.74%, respectively; P=0.01) and by 82% for pooled bosutinib versus placebo (0.84% versus 4.74%, respectively; P<0.001). Over the treatment period, patients receiving placebo or bosutinib had similar annualized eGFR decline. Gastrointestinal and liver-related adverse events were the most frequent toxicities. In conclusion, compared with placebo, bosutinib at 200 mg/d reduced kidney growth in patients with ADPKD. The overall gastrointestinal and liver toxicity profile was consistent with the profile in prior studies of bosutinib; no new toxicities were identified. (ClinicalTrials.gov: NCT01233869).

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Tesar V, Ciechanowski K, Pei Y, et al. Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2017. PMID: 28838955. doi:10.1681/ASN.2016111232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。